CDC-Funded Clinical Trial Proves UV Disinfection Effective in Decreasing C. diff and VRE Hospital-wide
A new study proves that enhanced terminal room disinfection with Tru-D SmartUVC leads to a decrease in risk of acquisition of targeted multidrug-resistant organisms such as C. diff and VRE for all patients, hospital-wide. The study, Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomized controlled trial with crossover design (BETR Disinfection), which was recently published in The Lancet Infectious Diseases, discusses the prescribed secondary analysis of the BETR-D randomized clinical trial.
The study authors believed from the outset that a measured dose of UV disinfection in targeted, “at-risk” rooms would have both direct effects on the next patient who entered the room and an indirect effect on all hospitalized patients, leading to a hospital-wide decreased risk of target organisms. Following the two-year, $2M, CDC-funded trial, the researchers concluded that, “Enhanced terminal room disinfection with UV in a targeted subset of high-risk rooms led to a decrease in hospital-wide incidence of C. difficile and VRE.”
Key takeaways from the study include:
- The initial BETR-D randomized clinical trial showed a risk reduction in all four MDROs. This new study demonstrates a decrease in the incidence of C. diff and VRE, hospital-wide.
- Adding UV disinfection to cleaning protocols not only makes the room safer for the next patient who enters, but it has an indirect effect on all hospitalized patients.
- Using UV for all contact precaution rooms and not just for the four targeted MDROs resulted in hospital-wide reductions.
- Regardless of whether the room had a patient previously infected or colonized with an MDRO, the study proves that adding UV disinfection to your cleaning protocols will result in fewer cases of C. diff and VRE hospital-wide.
- The data pool was very specific and excluded patients who had a targeted MDRO in the past 12 months or had a community-onset infection.
- The researchers stated that due to strict protocols and high compliance with manual cleaning and hand hygiene that, “The effects observed in our study might represent the minimum decrease achievable from enhanced disinfection strategies.”
Tru-D’s technology, when applied to “at risk” discharges, improves the outcomes for every patient who walks in the hospital doors. UV disinfection is an important piece of the puzzle that’s proven to reduce the incidence of infections in the hospital when “at-risk” rooms are targeted. Tru-D overcomes the limitations of standard disinfection and is a strategy to reduce the acquisition of MDROs, providing a safer environment for every patient who walks through the hospital doors.